Patterns of metastasis according to germline BRCA1/2 mutation status in patients with HER2-negative metastatic breast cancer
4 affiliations
- 1Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
- 2Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Via Gattamelata 64, 35128 Padova, Italy
- 3Hereditary Tumors Unit, Istituto Oncologico Veneto IRCCS, Padova, Italy
- 4Immunology and Molecular Oncology Diagnostics, Istituto Oncologico Veneto IRCCS, Padova, Italy
Abstract
BRCA1/2 pathogenic variants (PVs) may influence metastatic dissemination in breast cancer (BC), but existing data are often confounded by differences in subtype distribution among carriers. We assessed associations between germline BRCA1/2 status and metastatic sites in HER2-negative BC. Patients treated for HER2-negative metastatic BC (2007–2025) with known BRCA1/2 mutation status were identified. Metastatic sites at diagnosis and throughout the disease history were collected. CNS involvement included brain metastases and/or leptomeningeal involvement. Among 184 patients (33 BRCA1, 28 BRCA2, 123 noncarriers), 131 presented a HR + BC and 53 a triple negative BC (TNBC). In HR + BC, BRCA1/2 carriers presented less frequently bone metastases at first metastatic diagnosis (31.4% vs. 51.0%; p = 0.046). At a median follow-up of 80.7 months, among patients with HR + BC, BRCA1/2 carriers more frequently presented CNS involvement compared to noncarriers (31.4% vs. 14.6%, p = 0.030), with an earlier onset (24-month incidence: 23.4% vs. 5.2%; p = 0.041). In TNBC, BRCA1/2 carriers presented less frequently liver metastases (34.6% vs. 70.4%, p = 0.009), with similar CNS involvement (57.7% vs. 37%, p = 0.219). Germline BRCA1/2 PVs are associated with distinct metastatic patterns, including a higher and earlier risk of CNS involvement in HR + BCs. These findings may inform tailored radiological surveillance strategies.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13058-026-02374-w.
Related
- Exploring the role of local sequence context on patterns of germline mutation
- Divergent Prognostic Impact of Germline BRCA1 and BRCA2 Variants in Non-Metastatic Breast Cancer: A Real-World Cohort Study.
- Assessing germline genetic testing patterns, awareness, and adherence to guidelines among lebanese prostate cancer patients
- Single-cell and clinical analyses reveal elevated HAX1 expression and cell-cycle-associated programs during metastatic progression of lung adenocarcinoma, particularly in brain metastasis
- Influence of the male germline on B chromosome transmission in D. melanogaster
BibTeX
@article{bottosso2026patterns,
title = {{Patterns of metastasis according to germline BRCA1/2 mutation status in patients with HER2-negative metastatic breast cancer}},
author = {Michele Bottosso and Gaia Griguolo and Laura Trovò and Silvia Tognazzo and Giovanni Faggioni and Eleonora Mioranza and Grazia Maria Vernaci and Marina La Commare and Davide Massa and Giusy Landa and Davide Napetti and Alice Menichetti and Marco Montagna and Stefania Zovato and Maria Vittoria Dieci and Valentina Guarneri},
journal = {Breast Cancer Research : BCR},
year = {2026},
month = aug,
doi = {10.1186/s13058-026-02374-w},
url = {https://doi.org/10.1186/s13058-026-02374-w},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Patterns of metastasis according to germline BRCA1/2 mutation status in patients with HER2-negative metastatic breast cancer
AU - Michele Bottosso
AU - Gaia Griguolo
AU - Laura Trovò
AU - Silvia Tognazzo
AU - Giovanni Faggioni
AU - Eleonora Mioranza
AU - Grazia Maria Vernaci
AU - Marina La Commare
AU - Davide Massa
AU - Giusy Landa
AU - Davide Napetti
AU - Alice Menichetti
AU - Marco Montagna
AU - Stefania Zovato
AU - Maria Vittoria Dieci
AU - Valentina Guarneri
PY - 2026
DA - 2026/08/17
JO - Breast Cancer Research : BCR
DO - 10.1186/s13058-026-02374-w
UR - https://doi.org/10.1186/s13058-026-02374-w
AB - BRCA1/2 pathogenic variants (PVs) may influence metastatic dissemination in breast cancer (BC), but existing data are often confounded by differences in subtype distribution among carriers. We assessed associations between germline BRCA1/2 status and metastatic sites in HER2-negative BC. Patients treated for HER2-negative metastatic BC (2007–2025) with known BRCA1/2 mutation status were identified. Metastatic sites at diagnosis and throughout the disease history were collected. CNS involvement included brain metastases and/or leptomeningeal involvement. Among 184 patients (33 BRCA1, 28 BRCA2, 123 noncarriers), 131 presented a HR + BC and 53 a triple negative BC (TNBC). In HR + BC, BRCA1/2 carriers presented less frequently bone metastases at first metastatic diagnosis (31.4% vs. 51.0%; p = 0.046). At a median follow-up of 80.7 months, among patients with HR + BC, BRCA1/2 carriers more frequently presented CNS involvement compared to noncarriers (31.4% vs. 14.6%, p = 0.030), with an earlier onset (24-month incidence: 23.4% vs. 5.2%; p = 0.041). In TNBC, BRCA1/2 carriers presented less frequently liver metastases (34.6% vs. 70.4%, p = 0.009), with similar CNS involvement (57.7% vs. 37%, p = 0.219). Germline BRCA1/2 PVs are associated with distinct metastatic patterns, including a higher and earlier risk of CNS involvement in HR + BCs. These findings may inform tailored radiological surveillance strategies. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13058-026-02374-w.
SN - 1465-5411
SN - 1465-542X
ER -